EVOKE PHARMA, INC. Net Change in Cash
EVOKE PHARMA, INC. reported Net Change in Cash of -$2.02 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2025-11-13
- EVOKE PHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$972.51K, a 119.59% decline year-over-year.
- EVOKE PHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $4.96M.
- EVOKE PHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$1.63M.
- EVOKE PHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2022-03-31 was -$1.44M, a 114.27% decline year-over-year.
- EVOKE PHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $8.86M.
- EVOKE PHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$5.10M, a 830.24% decline from fiscal 2022.
- EVOKE PHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $698.99K, a 35.02% decline from fiscal 2021.
- EVOKE PHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2021 was $1.08M, a 55.27% decline from fiscal 2020.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2025-09-30 | -$2.02M 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | -$1.54M 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | -$972.51K 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $8.86M 10-K · filed 2025-03-13 | |||
| 2024-09-30 | $6.60M 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | $4.44M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | $4.96M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | -$5.10M 10-K · filed 2025-03-13 | |||
| 2023-09-30 | -$3.88M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | -$2.84M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | -$1.63M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $698.99K 10-K/A · filed 2024-05-14 | |||
| 2022-09-30 | $3.21M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $4.31M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | -$1.44M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $1.08M 10-K · filed 2023-03-21 | |||
| 2021-09-30 | $3.07M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | $8.65M 10-Q · filed 2022-08-10 | |||
| 2021-03-31 | $10.12M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $2.41M 10-K · filed 2022-03-08 | |||
| 2020-09-30 | $616.82K 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $2.33M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | -$1.53M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $344.83K 10-K · filed 2021-03-11 | |||
| 2019-09-30 | $1.19M 10-Q · filed 2020-11-10 | |||
| 2019-06-30 | $2.12M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | -$1.29M 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | -$2.36M 10-K · filed 2020-03-12 | |||
| 2018-09-30 | -$1.11M 10-Q · filed 2019-11-07 |